Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypersensitivity Reactions: Cytolytic Reactions01:01

Hypersensitivity Reactions: Cytolytic Reactions

Type II hypersensitivity involves IgG and IgM antibodies targeting cell surface antigens, leading to cell destruction. This can occur through complement activation, antibody-dependent cell-mediated cytotoxicity (ADCC), or acting as opsonins for phagocytosis. When excessive, these reactions cause significant tissue damage.Drug-induced hemolytic anemia is a common example, where drugs like penicillin or cephalosporins bind to red blood cells, forming drug-protein complexes. These complexes...
Drug toxicity: Drug–Drug Interaction01:30

Drug toxicity: Drug–Drug Interaction

Drug–drug interactions can precipitate toxicity through multiple mechanisms. Absorption interactions alter how drugs enter the body, exemplified when ranitidine increases the absorption of basic drugs, while cholestyramine decreases the levels of propranolol. Protein binding interactions occur when drugs share the same binding sites on plasma proteins. Drugs like aspirin and warfarin, when bound in excess, can lead to increased free drug concentrations, enhancing the potential for...
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allogeneic islet products for type 1 diabetes: Navigating nonclinical and manufacturing regulatory expectations.

Stem cell reports·2026
Same author

Co-ADAM: a co-evolutionary signaling game framework for equilibrium cyber deception in industrial IoT.

Scientific reports·2026
Same author

Wound Healing Activity of Iron Oxide Nanoparticles; Comparative In Vivo Study on <i>Staphylococcus aureus</i>-Infected and Non-Infected Wounds.

Antibiotics (Basel, Switzerland)·2026
Same author

Recent perioperative challenges in anesthesia during expansion of heart transplantation.

Journal of cardiothoracic surgery·2026
Same author

A Novel Hyaluronic Acid-Glycyrrhizic Acid Complex Mitigates γ-Radiation-Induced Neurotransmitter Damage in Rats.

Applied biochemistry and biotechnology·2026
Same author

Glucagon-like peptide 1 receptor agonist use and risk of arthroplasty for knee osteoarthritis: retrospective database analysis.

Regional anesthesia and pain medicine·2026

Related Experiment Video

Updated: May 11, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Ibuprofen-induced hemolytic anemia.

Aram Barbaryan1, Chioma Iyinagoro, Nwabundo Nwankwo

  • 1Department of Internal Medicine, Saint Joseph Hospital, 2900 N. Lake Shore, Chicago, IL 60657, USA.

Case Reports in Hematology
|May 28, 2013
PubMed
Summary
This summary is machine-generated.

Drug-induced immune hemolytic anemia is rare. A case study shows ibuprofen can cause this serious condition, leading to rapid red blood cell destruction. Prompt cessation of the drug resulted in recovery.

Related Experiment Videos

Last Updated: May 11, 2026

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions
08:56

Synthesis of a Borylated Ibuprofen Derivative Through Suzuki Cross-Coupling and Alkene Boracarboxylation Reactions

Published on: November 30, 2022

Area of Science:

  • Hematology
  • Pharmacology
  • Internal Medicine

Background:

  • Drug-induced immune hemolytic anemia (DIIHA) is a rare but serious adverse drug reaction.
  • It occurs due to antibodies against drug-erythrocyte complexes.
  • The incidence of DIIHA is estimated at 1 in a million.

Purpose of the Study:

  • To report a case of DIIHA.
  • To highlight ibuprofen as a potential causative agent.
  • To emphasize the importance of prompt diagnosis and drug withdrawal.

Main Methods:

  • Case report of a 36-year-old female.
  • Clinical presentation: shortness of breath, dark urine, pale mucous membranes.
  • Laboratory findings: severe anemia (Hb 4.9 g/dL), elevated LDH, reticulocytosis.
  • Exclusion of other causes of hemolytic anemia.

Main Results:

  • Patient presented with acute hemolytic anemia after ibuprofen use.
  • Ibuprofen was identified as the likely cause.
  • Discontinuation of ibuprofen led to rapid hematologic recovery within 3 days.

Conclusions:

  • Ibuprofen can induce immune hemolytic anemia.
  • Early recognition and withdrawal of the offending drug are crucial for patient recovery.
  • This case underscores the importance of considering drug-induced causes in new-onset hemolytic anemia.